The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Radiotherapy (RT) potentiation with weekly (q1w) or standard every 3 weeks (q3w) cisplatin chemotherapy (CT) for locally advanced head and neck squamous cell carcinoma (HNSCC).
Yann Molin
No relevant relationships to disclose
Emilie Lavergne
No relevant relationships to disclose
Pascal Pommier
No relevant relationships to disclose
Severine Racadot
No relevant relationships to disclose
Xavier Montbarbon
No relevant relationships to disclose
Marc Poupart
No relevant relationships to disclose
Philippe Zrounba
No relevant relationships to disclose
Philippe Ceruse
No relevant relationships to disclose
Jerome Fayette
No relevant relationships to disclose